Showing results (311-320 of 426) with videos related to
Sort By:
Pageof 43
JAMA Oncology|December 26, 2024
Deep Learning Model for Predicting Immunotherapy Response in Advanced Non-Small Cell Lung CancerMehrdad Rakaee, Masoud Tafavvoghi, Biagio Ricciuti, et al.Journal for Immunotherapy of Cancer|October 18, 2023
Increased interleukin-6/C-reactive protein levels are associated with the upregulation of the adenosine pathway and serve as potential markers of therapeutic resistance to immune checkpoint inhibitor-based therapies in non-small cell lung cancerAbdul Rafeh Naqash, Justin D McCallen, Emma Mi, et al.Journal for Immunotherapy of Cancer|October 8, 2020
Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapyDavid J Pinato, Ahmed Kaseb, Yinghong Wang, et al.Lung Cancer (Amsterdam, Netherlands)|February 22, 2023
Second-line treatment outcomes after progression from first-line chemotherapy plus immunotherapy in patients with advanced non-small cell lung cancerEdouard Auclin, Jose Benitez-Montanez, Marco Tagliamento, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 5, 2024
Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib StudyDavid J Pinato, Antonio D'Alessio, Claudia Angela Maria Fulgenzi, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 17, 2021
Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapyA Cortellini, B Ricciuti, F Facchinetti, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 27, 2026
Phase I Study of Mosperafenib, a Novel Paradox Breaker B-Raf Proto-Oncogene Serine/Threonine Kinase (BRAF) Inhibitor, in Patients With BRAF V600-Mutant Solid TumorsMaria Vieito, Elisa Fontana, Catherine H Han, et al.JAMA Network Open|June 4, 2025
Immune Checkpoint Inhibitors for Patients With Preexisting Autoimmune Neurologic DisordersKylie Fletcher, Marc Machaalani, Razane El Hajj Chehade, et al.Cambridge Prisms. Precision Medicine|February 13, 2025
UK cancer vaccine advance - Recognising and realising opportunitiesCharles Craddock, Philip Earwaker, Matthew Fittall, et al.The Lancet. Oncology|July 3, 2026
Differential impact of proton pump inhibitors and antibiotics on immunotherapy efficacy after chemoradiotherapy in locally advanced non-small-cell lung cancer: a post-hoc analysis of the PACIFIC trialLeonardo Brunetti, Valentina Santo, David J Pinato, et al.Pageof 43